SCHEMBL3977290

SCHEMBL3977290

CCOC(=O)c1occ(Br)c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.50
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 4/20 0.50
HPGD P15428 3/20 0.50
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
GAA P10253 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TDP1 Q9NUW8 1/20 0.46
TSHR P16473 2/20 0.45
GRM6 O15303 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PRNP P04156 1/20 0.44
PLK1 P53350 1/20 0.43
TARBP2 Q15633 1/20 0.42
AHR P35869 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3977508 0.83 JAK2 (0.48) MAPTMEN1KMT2AMAOB
SCHEMBL3977049 0.80 ALDH1A1 (0.47) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL8861328 0.78 FABP4 (0.41) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL4282758 0.78 CDC7 (0.48) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL11273191 0.77 MAPT (0.47) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL3979225 0.77 MAPT (0.41) MAPTALDH1A1KDM4ELMNAGAA
SCHEMBL3978078 0.77 ALDH1A1 (0.51) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL3973642 0.77 MAPT (0.46) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL3981475 0.74 GAA (0.45) MAPTALDH1A1KDM4EHPGDLMNA
SCHEMBL20028528 0.74 TSHR (0.54) MAPTALDH1A1KDM4EHPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100543022-C 2-furancarboxylic acid hydrazide compound and contain the pharmaceutical composition of this compound DAINIPPON PHARMACEUTICAL CO (JP) 2009-09-23 CN disclosed
US-7514452-B2 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD (JP) 2009-04-07 US disclosed
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2005-08-04 US disclosed
CN-1628111-A 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same DAINIPPON PHARMACEUTICAL CO (JP) 2005-06-15 CN disclosed
EP-1489077-A1 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171196-A1 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same GLP1R, GCGR, GPR119 MAPT 4833/4885ALDH1A1 1389/4885KDM4E 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.